Indee Labs, a Berkeley CA- and Sidney, Australia-based developer of hardware for gene delivery using microfluidic vortex shedding (µVS), raised US$2.6M in seed financing.
The round, which extended its seed funding to more than US$5.4M (AU$7.1M), was led by Founders Fund (San Francisco) and included Main Sequence Ventures (Australia) along with several angels.
The company intends to use the funds to build the team and accelerate the development of its gene therapy manufacturing technology into a product that biotechnology companies can use for discovery-stage research.
Led by Ryan Pawell, CEO, Indee Labs, Amy Twite PhD, Chief Scientific Officer, and Warren McKenzie, CEO, Indee Labs Australia, the company Indee is developing hardware for gene delivery using microfluidic vortex shedding (µVS).
The tech platform can rapidly process clinically- and commercially-relevant samples with no observed immune cell perturbation.